Press releases
- Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
- Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
- Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
- Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
- Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
- Veracyte Completes Acquisition of C2i Genomics
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.50 |
---|---|
High | 17.50 |
Low | 17.50 |
Bid | 18.00 |
Offer | 18.10 |
Previous close | 17.70 |
Average volume | 9.33 |
---|---|
Shares outstanding | 78.44m |
Free float | 77.54m |
P/E (TTM) | -- |
Market cap | 1.48bn USD |
EPS (TTM) | -1.02 USD |
Data delayed at least 15 minutes, as of Apr 18 2024 07:02 BST.
More ▼